Saik Andrew 4

What Happened
Andrew Saik, a director of Milestone Pharmaceuticals, was granted a derivative award covering 77,000 shares on June 10, 2026. The Form 4 reports the acquisition as an award/derivative at $0.00 (no cash paid at grant); the filing shows this as an option grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-10; Form 4 filed 2026-06-12 (timely filing).
• Reported consideration: $0.00 per share on the Form 4 (derivative award).
• Amount: 77,000 shares (derivative securities/options).
• Shares owned after transaction: not specified in the provided details.
• Footnote: The option vests in twelve equal monthly installments starting July 10, 2026, and will fully vest on the date of the next annual stockholders’ meeting, provided the reporting person continues service (see footnote F1).
• Insider status: Director (not a 10% owner or officer in this filing).

Context
This was a grant of an option-style award, not an immediate purchase or sale of common stock; options vest over time and must typically be exercised later to convert to shares. The $0.00 figure on the Form 4 reflects that no cash changed hands at grant for reporting purposes; consult company disclosures or prospectus for any exercise price or additional award terms.